Lifeworks Advisors LLC Purchases Shares of 452 Thermo Fisher Scientific Inc. (NYSE:TMO)

Lifeworks Advisors LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, HoldingsChannel.com reports. The fund purchased 452 shares of the medical research company’s stock, valued at approximately $225,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Capital World Investors increased its holdings in Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock valued at $4,905,812,000 after acquiring an additional 104,343 shares during the last quarter. Geode Capital Management LLC increased its holdings in Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock valued at $4,075,540,000 after acquiring an additional 197,442 shares during the last quarter. Northern Trust Corp grew its stake in shares of Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after buying an additional 455,004 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock worth $1,604,338,000 after buying an additional 1,433,444 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in shares of Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock worth $1,432,816,000 after buying an additional 193,378 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.8%

Shares of TMO opened at $478.61 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a 50-day moving average of $413.76 and a 200 day moving average of $470.22. The firm has a market capitalization of $180.67 billion, a price-to-earnings ratio of 27.68, a PEG ratio of 2.47 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.36%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Analyst Ratings Changes

A number of brokerages have commented on TMO. Royal Bank Of Canada dropped their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an “equal weight” rating in a research note on Thursday. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a research note on Friday, July 11th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.